The 8th EBOVAC2 newsletter is available here. This newsletter announces the European Commission Approval for Janssen's Ebola vaccine regimen.
Johnson & Johnson announced on 1st July 2020 that the European Commission (EC) has granted Marketing Authorisation for its Janssen Pharmaceutical Companies’ Ebola vaccine regimen developed in partnership with Bavarian Nordic for the prevention of Ebola Virus Disease. The full press release can be found HERE.
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola Vaccine Regimen. The full press release can be found here
An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!
Page 1 of 7
NEWS
-
8th EBOVAC2 Newsletter
The 8th EBOVAC2 newsletter is available here. This newsletter announces the European Commission...
-
European Commission Approval for Janssen’s Ebola vaccine regimen
Johnson & Johnson announced on 1st July 2020 that the European Commission (EC) has granted...
-
Positive CHMP Opinion for Janssen's Ebola Vaccine Regimen
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola...
-
Ebovac2 at ECCMID 2019
An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the...
-
7th EBOVAC2 Newsletter
The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi...
-
Ebola: background
What is Ebola?
-
Phase 2 trials
Find out more about EBOVAC2 trials
-
Work programme
EBOVAC2 is organised into 6 workpackages (WP)
-
Ebola+ programme
Contributes to efforts to tackle a wide range of challenges in Ebola research
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA